This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.83% per year. These returns cover a period from January 1, 1988 through January 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat '26 EPS View
by Zacks Equity Research
Biogen tops Q4 earnings and sales estimates, and shares rise after the company issues an encouraging 2026 adjusted EPS outlook despite revenue pressure.
BIIBPositive Net Change RHHBYPositive Net Change SUPNPositive Net Change
biotechs earnings medical pharmaceuticals
Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push
by Kinjel Shah
PFE is betting on obesity and oncology in 2026, lining up 20 pivotal studies after $9B in 2025 M&A.
PFEPositive Net Change NVOPositive Net Change MRKPositive Net Change LLYPositive Net Change
pharmaceuticals
Merck's Subdued 2026 Outlook: What it Means After Q4 Results?
by Kanishka Das
MRK posts conservative 2026 sales and EPS outlook, given acquisition charges. Keytruda, Animal Health and new drug launches are expected to drive 2026 growth.
JNJPositive Net Change MRKPositive Net Change UTHRPositive Net Change
pharmaceuticals
Bayer's Asundexian Shows 26% Stroke Reduction in Late-Stage Study
by Zacks Equity Research
Bayer presents positive data on asundexian, which shows superior efficacy with no added bleeding risk, boosting hopes for regulatory approval.
JNJPositive Net Change BAYRYNegative Net Change CYTKPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO, LLY Stocks Slide as HIMS Launches $49 Compounded Semaglutide Pill
by Ekta Bagri
HIMS shakes up the weight loss market with a $49 compounded semaglutide pill, pressuring Novo Nordisk and Eli Lilly shares and sparking FDA and legal pushback.
NVOPositive Net Change LLYPositive Net Change HIMSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Incyte Gears Up to Report Q4 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
INCY heads into Q4 earnings with strong Jakafi sales, rising royalties and multiple new launches contributing to revenues, setting the stage for a potential upside surprise.
NVSPositive Net Change LLYPositive Net Change INCYPositive Net Change MRNAPositive Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
Weekly Jobless Claims Exceed Expectations
by Zacks Equity Research
Weekly Jobless Claims Exceed Expectations.
BMYPositive Net Change COPPositive Net Change MTPositive Net Change HSYPositive Net Change RLPositive Net Change MCFTPositive Net Change TPRPositive Net Change
basic-materials consumer-discretionary pharmaceuticals retail
Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
BMY beats Q4 earnings and revenue estimates as its Growth Portfolio jumps 16%, lifting shares despite continued declines in legacy drugs.
BMYPositive Net Change PFEPositive Net Change ALKSPositive Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Jobless Claims Pop Up a Bit, Major Morning for Earnings
by Mark Vickery
Jobless Claims notched their highest weekly print since early December, while BMY, RL, COP & more report earnings.
BMYPositive Net Change COPPositive Net Change MTPositive Net Change HSYPositive Net Change RLPositive Net Change MCFTPositive Net Change TPRPositive Net Change
apparel earnings industrial-products pharmaceuticals staffing
Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
NBIX heads into fourth-quarter earnings with Ingrezza sales strength, growing Crenessity revenues and rising focus on late-stage pipeline updates.
MRNAPositive Net Change NBIXPositive Net Change CRSPPositive Net Change CSTLPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals